Lawrence Hauser
Psychiatry · Austin, TXNPI 1750391553
Payments from drug & device makers
Across 439 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$578
- Lundbeck LLC$575
- Neurocrine Biosciences, Inc.$509
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,761100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 98 | $1,502 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 57 | $1,130 |
| Alkermes, Inc. | 63 | $1,039 |
| Otsuka America Pharmaceutical, Inc. | 31 | $578 |
| Lundbeck LLC | 28 | $575 |
| Neurocrine Biosciences, Inc. | 25 | $509 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $423 |
| Axsome Therapeutics, Inc. | 16 | $340 |
| Sunovion Pharmaceuticals Inc. | 23 | $323 |
| Bausch Health US, LLC | 13 | $276 |
| Johnson & Johnson | 13 | $231 |
| E.r. Squibb & Sons, L.L.C. | 10 | $185 |
| Vanda Pharmaceuticals Inc. | 8 | $154 |
| Ironshore Pharmaceuticals Inc. | 5 | $99 |
| Alfasigma USA, Inc. | 5 | $76 |
| Inspire Medical Systems, Inc. | 2 | $56 |
| Supernus Pharmaceuticals, Inc. | 3 | $55 |
| Corium, LLC | 3 | $47 |
| Avanir Pharmaceuticals, Inc. | 2 | $41 |
| Shire North American Group Inc | 2 | $39 |
| Collegium Pharmaceutical, Inc. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| OWP Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$7,777 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 25 | $35,456 |
| RexultiBrexpiprazole | 17 | $23,528 |
| Clozapine | 62 | $5,555 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 51 | $4,247 |
| Vilazodone Hcl | 40 | $3,922 |
| Duloxetine Hcl | 99 | $2,321 |
| Gabapentin | 96 | $2,214 |
| Quetiapine Fumarate | 69 | $1,932 |
| Aripiprazole | 63 | $1,818 |
| Lurasidone Hcl | 31 | $1,751 |
| Trazodone Hcl | 115 | $1,739 |
| Fluoxetine Hcl | 83 | $1,557 |
| Escitalopram Oxalate | 56 | $1,537 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 43 | $1,262 |
| Bupropion XlBupropion Hcl | 48 | $1,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,502 | $35,45625 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $578 | $23,52817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Austin
- David BrownAustin$15.8M
- Divyansu PatelAustin$2.8M
- Donald GarciaAustin$2.8M
- Arvinder Pal WaliaAustin$2.5M
- Charles SweetAustin$520K
- Charles NemeroffAustin$429K
- Scott BartleyDallas$42.7M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.